| A new method for vitrifying samples for cryoEM I Razinkov, VP Dandey, H Wei, Z Zhang, D Melnekoff, WJ Rice, C Wigge, ... Journal of structural biology 195 (2), 190-198, 2016 | 144 | 2016 |
| Mutation-derived neoantigen-specific T-cell responses in multiple myeloma D Perumal, N Imai, A Laganà, J Finnigan, D Melnekoff, VV Leshchenko, ... Clinical Cancer Research 26 (2), 450-464, 2020 | 78 | 2020 |
| Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma A Laganà, D Perumal, D Melnekoff, B Readhead, BA Kidd, V Leshchenko, ... Leukemia 32 (1), 120-130, 2018 | 70 | 2018 |
| Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications S Bhalla, DT Melnekoff, A Aleman, V Leshchenko, P Restrepo, J Keats, ... Science Advances 7 (47), eabg9551, 2021 | 65 | 2021 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 53 | 2023 |
| Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach A Laganà, I Beno, D Melnekoff, V Leshchenko, D Madduri, D Ramdas, ... JCO precision oncology 2, 1-17, 2018 | 36 | 2018 |
| Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma TH Mouhieddine, O Van Oekelen, DT Melnekoff, J Li, Y Ghodke-Puranik, ... Blood advances 7 (6), 1056-1064, 2023 | 29 | 2023 |
| A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma O Van Oekelen, S Parekh, HJ Cho, N Vishnuvardhan, D Madduri, ... Leukemia & lymphoma 61 (9), 2208-2215, 2020 | 15 | 2020 |
| A three-gene signature predicts response to selinexor in multiple myeloma P Restrepo, S Bhalla, Y Ghodke-Puranik, A Aleman, V Leshchenko, ... JCO Precision Oncology 6, e2200147, 2022 | 13 | 2022 |
| Single-cell sequencing technologies in precision oncology DT Melnekoff, A Laganà Computational Methods for Precision Oncology, 269-282, 2022 | 11 | 2022 |
| Single-cell profiling reveals contribution of tumor extrinsic and intrinsic factors to BCMA-targeted CAR-T cell efficacy in multiple myeloma DT Melnekoff, Y Ghodke-Puranik, O Van Oekelen, A Aleman, ... Blood 138, 326, 2021 | 6 | 2021 |
| Clinical outcomes and treatment strategies for relapsed/refractory myeloma patients after relapse on BCMA-targeted CAR T O Van Oekelen, TH Mouhieddine, D Pan, M Metzger, S Agte, A Aleman, ... Blood 138, 2704, 2021 | 6 | 2021 |
| ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes RN Tasakis, A Laganà, D Stamkopoulou, DT Melnekoff, P Nedumaran, ... Biorxiv, 2020.02. 11.943845, 2020 | 6 | 2020 |
| E2F1 is a biomarker of selinexor resistance in relapsed/refractory multiple myeloma patients A Lagana, S Park, D Edwards, V Leshchenko, M Crochiere, Y Landesman, ... Blood 132, 3216, 2018 | 6 | 2018 |
| Increased HLA-E expression correlates with early relapse in multiple myeloma A Lagana, DF Ruan, D Melnekoff, V Leshchenko, D Perumal, A Rahman, ... Blood 132, 59, 2018 | 6 | 2018 |
| Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation M Elnaggar, S Agte, P Restrepo, M Ram, D Melnekoff, C Adamopoulos, ... Journal of Hematology & Oncology 15 (1), 109, 2022 | 5 | 2022 |
| Clonal evolution in newly diagnosed multiple myeloma patients: a follow-up study from the Mmrf Commpass Genomics Project A Lagana, D Melnekoff, I Beno, V Leshchenko, D Perumal, JJ Keats, ... Blood 130, 325, 2017 | 4 | 2017 |
| Network modeling reveals CDC42BPA and CLEC11A as novel driver genes of t (4; 14) multiple myeloma D Perumal, D Melnekoff, B Readhead, B Kidd, VV Leshchenko, PY Kuo, ... Blood 128 (22), 802, 2016 | 3 | 2016 |
| Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in … JV dos Santos, D Melnekoff, A Aleman, S Bhalla, TH Mouhieddine, ... Blood 142, 93, 2023 | 2 | 2023 |
| Pathogenic germline variants in multiple myeloma S Thibaud, A Etra, R Subaran, Z Soens, S Newman, R Chen, A Chari, ... Blood 138, 399, 2021 | 2 | 2021 |
Alessandro LaganàAssistant Professor of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY在 mssm.edu 的电子邮件经过验证
